Covid vaccine delivered by HD-map

The high-density microprojection array (HD-MAP) for transdermal delivery of the HexaPro vaccine composition addresses the reduced efficacy of COVID-19 vaccines against SARS-CoV-2 variants by providing a stable and efficient immunization method, enabling storage at room temperature and achieving robust immune responses.

WO2024250040A2PCT designated stage expired Publication Date: 2024-12-05VAXXAS PTY LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/039247
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-07-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current COVID-19 vaccines face challenges with reduced efficacy against SARS-CoV-2 variants due to antigenicity changes in the spike protein, and existing administration methods require cold storage and intramuscular injection, which are not ideal for dose sparing and flexibility.

Method used

The use of a high-density microprojection array (HD-MAP) for transdermal delivery of the HexaPro vaccine composition, which includes saponin, coated onto microprojections that penetrate the skin, providing a stable and efficient route for immunization against SARS-CoV-2 variants, allowing for storage at room temperature and potentially dose-sparing advantages.

Benefits of technology

The HD-MAP technology achieves significant immune responses with high delivery efficiency, stability of the vaccine at 2-8°C for six months, and effective transdermal delivery of the vaccine, overcoming the limitations of traditional intramuscular injection and cold storage requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024039247_05122024_PF_FP_ABST
    Figure US2024039247_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A method of immunizing a human against SARS-CoV-2 by administering to the human a HexaPro vaccine composition coated onto a microprojection array (HD-MAP) comprising a base and a plurality of solid microprojections by projecting the microprojection array into the human's skin thereby penetrating the skin with the microprojections coated with the composition such that the vaccine composition is stripped from the microprojections.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Covid Vaccine Delivered by HD-MAP Related Applications This application claims priority to U.S. Ser. No.63 / 470,600filed on June 2, 2023, which is incorporated in its entirety into this application. Field of the Invention The present invention relates to stable vaccine formulations for administration via a microprojection array in which the microprojections are densely packed and in which the vaccine formulations are rapidly sprayed or layered on to the microprojections in relatively small amounts such that the formulations dry rapidly. The present invention relates in particular to Covid spike protein vaccines delivered by high density micro-array MAPs (HD-MAP). Background of the Invention Since December 2019, SARS-CoV-2 (Severe Acute Respiratory Syndrome-related Coronavirus-2) has been responsible for a worldwide pandemic. screening for anti-S or anti-RBD antibodies can be used to search for the presence of humoral immune markers after a Covid infection (or to signal a previous contact if diagnosis could not be made), as they seem to persist for longer than anti-N antibodies. Currently, the emergence offive VOCs, including B.1.1.7 (Alpha), P.1 (Gamma), B.1.351 (Beta), B.1.617.2 (Delta), and Omicron (B.1.1.529) have drawn broad attention due to their altered pathogenicity and transmissibility as well as reduced sensitivity to vaccine-elicited sera or monoclonal antibodies (mAbs), endangering worldwide efforts to control COVID-19. SARS-CoV-2 spike protein plays a critical role in viral attachment and fusion with the host cell. Therefore, the majority of antibodies that neutralize viral infection target the spike protein, making it an ideal antigen to elicit potent protective immunity from SARS-CoV-2 infection. However, mutations from the SARS-CoV-2 variants located on the spike protein extensively affected its antigenicity, leading to broad antibody resistance and immune escape from vaccinate-elicited sera. WO 2021 / 243122 describes engineered coronavirus spike proteins which exhibit enhance conformational stability and when expressed in cells produces up to 10 times more protein than that of an earlier synthetic spike protein already in use in multiple COVID-19 vaccines. The engineered spike proteins introduce prolines into the protein and in one case the prolines are introduced as follows: F817P, A892P, A899P, A942P, K986P, and V987P. The substitution of prolines can be accomplished in any of the covid variants to provide a more stable spike protein. While the current SARS-CoV-2 vaccines are given intramuscularly it would be advantageous to provide a different route of administration especially if the alternative could be dose sparing and provide other advantages such as the ability to store at room or refrigerated (2-8°C) temperatures. One alternative is a high-density microprojection array patch (HD-MAP) which contains microprojections which are microscopic structures associated with the array that are capable of piercing the stratum corneum to facilitate transdermal delivery of therapeutic agents through or to the skin. Microprojections may include needle or needle-like structures, micro-pins as well as solid projections of a variety of sizes and shapes.

[0002] Summary of the Invention The present invention relates to methods of immunizing a human against SARS-CoV-2 by administering to the human a HexaPro vaccine composition coated onto a microprojection array (HD-MAP) having a base and a plurality of solid microprojections by projecting the microprojection array into the human’s skin thereby penetrating the skin with the microprojections coated with the composition such that the vaccine composition is stripped from the microprojections. The present invention relates to methods where the HexaPro vaccine composition is selected from the HexaPro wild-type, HexaPro alpha, HexaPro beta, HexaPro gamma, HexaPro delta, HexaPro omicron and combinations thereof. The present invention relates to methods where the number of microprojections is between 1500 and 3000. The present invention relates to methods where the length of the microprojections is between 200 to 400µm. The present invention relates to methods where the HexaPro vaccine composition comprises a saponin. The present invention relates to methods where the saponin is QS-21. The present invention relates to methods where the HexaPro vaccine composition is a dose of between 15 to 30µg. The present invention relates to methods where the HexaPro vaccine composition is stable for 6 months at 2-8°C. The present invention relates to methods where the amount of HexaPro vaccine composition that is stripped from the microprojections is from about 50 to 90% of the amount of HexaPro vaccine composition coated onto the microprojections. The present invention relates to methods where the microprojection array is projected at the skin at a velocity of about 20 to 26 meters per second. The present invention relates to methods where the administration to the human is accomplished by multiple doses of the HexaPro vaccine composition. The present invention relates to methods where the microprojection array remains in the skin of the human for at least 3 seconds. Brief Description of the Figures Figure 1 – Plot of fold change on a per subject basis for each functional IgG assay by group. Figure 2 – Plot of fold titer change day 0 to day 28 versus day 0 titer. Figure 3A – Plot of Median + / - 95% CI versus Anti-RBD median titers for the groups at day 0 and day 28; Figure 3B – Plot of Median + / - 95% CI versus Anti-Spike median titers for the groups at day 0 and day 28. Figure 4 - Plot of Median + / - 95% CI versus log10 Anti-RBD median titers for the groups at day 0 and day 28 Figure 5 -Bar graph of anti-RBD (BAU / ml) for uncoated HD-MAP, 30mcg coated HD- MAP and 90 mcg coated HD-MAP at days 0 and 28 (include anomalous data point). Figure 6 – Plot of difference between day 0 and day 28 anti-RBD IgG titer (BAU / ml) for uncoated HD- MAP, 30mcg coated HD- MAP and 90 mcg (include anomalous data point). X equals the mean. Figure 7 -Bar graph of anti-RBD (BAU / ml) for uncoated HD-MAP, 30mcg coated HD- MAP and 90 mcg coated HD-MAP at days 0 and 28 (excludes anomalous data point). Figure 8 – Plot of difference between day 0 and day 28 anti-RBD IgG titer (BAU / ml) for uncoated HD- MAP, 30mcg coated HD- MAP and 90 mcg (excludes anomalous data point). X equals the mean. Figure 9 – Plot of anti-spike (BAU / ml) for uncoated HD-MAP, 30mcg coated HD- MAP and 90 mcg coated HD-MAP at days 0 and 28 (excludes anomalous data point). Figure 10 – Plot of difference between day 0 and day 28 anti-spike IgG titer (BAU / ml) for uncoated HD- MAP, 30mcg coated HD- MAP and 90 mcg (excludes anomalous data point). X equals the mean. Figure 11 – Plot of Delivery Efficiency versus Wear Time for tip configuration Figure 12 - Plot of Delivery Efficiency versus Wear Time for step configuration Figure 13 - Plot of Delivery Efficiency versus Wear Time for both configurations Figure 14 - Plot of Delivery Efficiency versus Coating Configurations for all Time points Figure 15 – Plot of log10 PRNT50for each group for A) QLD02, B) alpha and C) delta SARS-Co-V-2 strains at day 20 Figure 16 – Plot of log10 PRNT50for each group for A) QLD02, B) alpha and C) delta SARS-Co-V-2 strains at day 42 Figure 17 – Bar graph of A) alpha peptide stimulation for all groups and B) delta peptide stimulation for all groups Figure 18 – Bar graph of A) CD4 T cell response for alpha peptide stimulation for all groups and B) CD4 T cell response for delta peptide stimulation for all groups Figure 19 – Bar graph of A) CD8 T cell response for alpha peptide stimulation for all groups and B) CD4 T cell response for delta peptide stimulation for all groups Figure 20 – Bar graph of log10 PRNT50for each group for A) QLD02, B) alpha and C) delta SARS-Co-V-2 strains Figure 21 – Graph of clinical score versus days post infection for naïve, HD-MAP and ID administration. Figure 22 – Bar graph of viral load in the lungs for naïve, HD-MAP and ID administration Figure 23 – Bar graph of ELISA results of A) IgG versus delta and B) IgG versus wild-type for naïve, HD- MAP and ID administration. Figure 24 – Plot of Log10 ELISA EC50 titer for naïve, HexaPro ID, HexaPro HD-MAP, HexaPro + QS-21 ID, HexaPro + QS-21 HD-MAP at day 20. Figure 25 – Plot of Log10 ELISA EC50 titer for naïve, HexaPro ID, HexaPro HD-MAP, HexaPro + QS-21 ID, HexaPro + QS-21 HD-MAP at day 42 for A) wild-type, B) delta and C) omicron. Figure 26 – Representation of A) HD-MAP application, skin B) sampling and sectioning, C) staining, and D) transcriptomics analysis Figure 27 – Scatter plot and enrichment score of genes in the dermis 24h after HD-MAP application. Figure 28 – Scatter plot and enrichment score of genes in the dermis after HD-MAP + HexaPro application. Figure 29 – Scatter plot and enrichment score of genes in the dermis after HD-MAP + HexaPro + QS-21 application Figure 30 – Scatter plot and enrichment score of genes in the epidermis 24h after HD-MAP application. Figure 31 – Scatter plot and enrichment score of genes in the epidermis after HD-MAP + HexaPro application. Figure 32 – Scatter plot and enrichment score of genes in the epidermis after HD-MAP + HexaPro + QS- 21 application Detailed Description of the Invention The present invention relates to HD-MAPs and their use in the immunization of patients with respect to vaccines, in particular the SARS-CoV-2 spike protein vaccines. HD-MAPs are microprojection arrays having projections extending from the surface of a base. The projections and base may be formed from any suitable material, including but not limited to silicon and various polymers including liquid crystal polymers. The projections may be solid, non-porous and non-hollow. The HD-MAP may have a square, rectangular or irregular shape depending on its use, but other arrangements of projections such as circular arrangement of the projections that are compatible with rotational spray coating may also be used. In order to further improve or enhance the targeting accuracy, the substrate may be designed such that the features to be coated are located on radial lines from the center point of the rotation or located on concentric circles or on a continuous spiral. The substrate may be designed such that the feature spacing on each arc is designed to match an integer number of steps of the motor for a given radius. Each projection includes a tip for penetrating tissue of the biological subject and projections will typically have a profile which tapers from the base to the tip. The HD-MAP is applied to the biological subject by positioning the MAP against a surface of a subject or by positioning the HD-MAP near the subject if an applicator that can propel the HD-MAP toward the skin is utilized. The tips of the projections penetrate the surface of the skin and may penetrate tissue beneath the surface of the skin to a given depth as the MAP is applied. The MAP may be used to deliver material or stimulus to internal tissues of a patient. The MAP may be delivered such that the projections pierce the Stratum Corneum (SC) and penetrate through the Viable Epidermis VE to penetrate the Dermis (DE) by a dermal penetration depth. The MAP may be used to deliver material or stimulus to any part or region in the subject. The MAP can be provided in a variety of different configurations to suit different material or stimulus delivery requirements. Accordingly, the specific configuration of the MAP can be selected to allow the delivery of material and stimulus to particular tissues, at a specific depth, to induce a desired response. The microprojection arrays can be varied in size depending on its use. The area of the MAP will have an impact on the ability to penetrate the subject, but this must be balanced by the need to induce cell damage over a sufficiently large area to induce a response. Consequently the MAPs typically have dimensions of between 0.5 x 0.5 mm and 20 x 20 mm, between 0.5 x 0.5 mm and 15 x 15 mm and more typically between 1 x 1 mm and 12 x 12 mm. In one embodiment the microprojection array is 10.6x10.6mm. The microprojection arrays may have a density of projections of between from 1,000 to 5,000 per cm2, or from 2,500 to 20,000 per cm2or from 2,500 to 15,000 per cm2or from 2,500 to 10,000 per cm2or from 2,500 to 7,500 per cm2or from 2,500 to 5,000 per cm2or from 5,000 to 20,000 per cm2or from 5,000 to 15,000 per cm2or from 5,000 to 10,000 per cm2or from 5,000 to 9,000 per cm2or from 5,000 to 8,000 per cm2or from 5,000 to 7,000 per cm2or from 5,000 to 6,000 per cm2. The applicators of the present invention are often utilized to project high density microprojection arrays into the skin. Such high density arrays are microprojection arrays of sufficient size and density such that forces that can be applied manually will be insufficient to overcome the elasticity of the skin. The microprojection array may be made of any suitable materials including but not limited to silicon, polymers, and plastic. In silicon embodiments the base thickness is about 60 um or silicon with a thin (1mm) polymer backing. The overall mass of some embodiments of the microprojection array is about 0.8 gm. The microprojection array may have bevelled edges to reduce peak stresses on the edge of the array. The MAP can be quartered or subdivided by other ratios to reduce the stress load on the MAP and mitigate MAP breakage. Polymer embodiments may have reduced mass. The microprojection array may also have an overall weakly convex shape of the MAP to improve the mechanical engagement with skin and mitigate the effect of high-speed rippling application: a ‘high velocity / low mass’ system. The microprojection array may have a mass of less than 1 gram, or less than 0.9 grams or less than 0.8 grams or less than 0.7 grams, or less than 0.6 grams or less than 0.5 grams or less than 0.4 grams. The microprojection array may have a mass of from about 0.1 grams to about 1.0 grams or from about 0.1 grams to about 0.9 grams, or from about 0.1 grams to about 0.8 grams or from about 0.1 grams to about 0.7 grams, or from about 0.1 grams to about 0.6 grams or from about 0.1 grams to about 0.5 grams or from about 0.1 grams to about 0.4 grams, or from about 0.1 grams to about 0.3 grams or from about 0.1 grams to about 0.2 grams. In one embodiment of the applicator / microprojection system the mass of the array is about 0.3 grams, the array is projected at a velocity of about 20-26 m / s by the applicator. The projection spacing is selected so that material from the projections is able to at least partially, and optionally at least completely, diffuse between the projections. Accordingly, the projections are typically separated by between 10 µm and 200 µm or between 10 µm and 190 µm or between 10 µm and 180 µm or between 10 µm and 170 µm or between 10 µm and 160 µm or between 10 µm and 150 or between 10 µm and 140 µm or between 10 µm and 130 µm or between 10 µm and 120 µm or between 10 µm and 110 µm or between 10 µm and 100 µm or between 10 µm and 90 µm or between 10 µm and 80 µm or between 10 µm and 70 µm or between 10 µm and 60 µm or between 10 µm and 50 µm or between 10 µm and 40 µm or between 10 µm and 30 µm or between 10 µm and 20 µm The amount of antigen used in the devices and methods of the present invention include amounts necessary to provide an immune response. At least one dose selected from the group consisting of a 1µg dose, 2µg dose, 3µg dose, 4µg dose, 5µg dose, 6µg dose, 7µg dose, 8µg dose, 9µg dose, 10µg dose, 15µg dose, 20µg dose, 25µg dose and a 30µg dose may be sufficient to induce an immune response in humans. The dose of the antigen may be administered to the human within a range of doses including from about 1μg to about 50μg, from about 1μg to about 30μg, from about 1μg to about 25μg, from about 1μg to about 20μg, from about 1μg to about 15μg, from about 1μg to about 10μg, from about 2μg to about 10μg, from about 2μg to about 8μg, from about 3μg to about 10μg, from about 3μg to about 8μg, from about 3μg to about 5μg, from about 4μg to about 10μg, from about 4μg to about 8μg, from about 5μg to about 10μg, from about 5μg to about 9μg, and from about 5μg to about 8μg. More than one dose may be appropriate for SARS-CoV-2 vaccines. Excipients may be included in the vaccine and include but are not limited to Histidine, Sodium acetate, Sodium chloride, Sodium citrate, Sodium phosphate, Sodium sulfate, Sodium succinate, Gelatin, Hydrolysed Gelatin,, Protamine sulfate, Arginine, Aspartic acid (sodium salt), Glutamic acid, Glycine, Isoleucine, Lactic acid, Lysine, Maleic acid, Malic acid (sodium salt), Methionine, Urea, EDTA, Magnesium chloride, Benzalkonium chloride, Brij 35, Poloxamer 188 (Pluronic F-68), Polysorbate 20, Polysorbate 80, Sodium docusate, Triton X-100, Lactose, Sucrose, Trehalose, Glycerol, Mannitol, Sorbitol, Gamma- Cyclodextrin, 2-OH propyl b-CD, Sulfobutyl ether beta-cyclodextrin, Carboxymethyl cellulose, Dextran sulfate, Dextran 40, PEG-3350, Sodium Hyaluronate, Sodium thioglycolate, Cysteine, and Glutathione, saponins (such as QS-21) and combinations thereof. Stability of vaccine compositions and components can be measured by a loss in antigen potency. This loss in potency can be determined under a variety of conditions, such as storage temperature and storage humidity at various time points. Typically, vaccines which are in solution are stored at 4°C or at room temperature (about 25°C). It would be preferable to be able to store vaccine at at least room temperature or higher temperatures (35°C - 45°C) such that cold storage would be unnecessary. The methods and compositions of the present invention provide microprojection arrays that can be coated with multiple incompatible vaccine antigens that are stable over time. The vaccine compositions of the present invention are stable at at least 2-8°C for at least 1 or at least 2 or at least 3 or at least 4 or at least 5 or at least 6 or at least 7 or at least 8 or at least 9 or at least 10 or at least 12 or at least 13 or at least 14 or at least 15 or at least 16 or at least 17 or at least 18 or at least 19 or at least 20 or at least 21 or at least 22 or at least 23 or at least 24 or at least 30 or at least 36 months at various temperatures and conditions. The stability of the vaccine formulations may be measured by a variety of techniques including but not limited to ELISA and SDS-PAGE silver stain. Vaccines of the present invention relate to the spike protein of the SARS-CoV-2 virus including all its variants including but not limited to wild-type, alpha, delta, omicron, beta and gamma and to the HexaPro (six proline substitutions) versions of each of the variants. For example, the HexaPro omicron vaccine is the omicron spike protein amino acid sequence with six proline substitutions that stabilize the spike protein. The vaccines of the present invention may be spray coated onto the HD-MAPs which minimizes the inefficiencies associated with spray coating or dip coating that may overcoat or undercoat the microprojections. Moreover, dip coating or spray coating is less accurate than ink jet coating. US 11254126 describes the process for coating microprojections of the HD-MAP. Once the vaccine is coated onto the microprojections of the HD-MAP it dries rapidly to form a stable coating on the microprojection arrays. When the HD-MAP is projected into the skin the vaccine coating is stripped from the microprojections and enters the skin. The efficiency of the stripping of the coating from the microprojections is about 40% or about 50% or about 60% or about 70% or about 80% or about 90% or about 95%. The efficiency of the stripping of the coating from the microprojections is from about 40 to 95% or from about 40 to 90% or form about 40 to 80% or from about 40 to 70% or from about 40 to 60% or from about 40 to 50% or from about 50 to 95% or from about 50 to 90% or form about 50 to 80% or from about 50 to 70% or from about 50 to 60% or from about 60 to 95% or from about 60 to 90% or form about 60 to 80% or from about 60 to 70% or from about 70% to 95% or from about 70 to 90% or form about 70 to 80%. Examples Example 1 Human Clinical Trial The study was a single-centre, randomised, blinded study conducted in two parts, there were 44 healthy adults aged 18–50 years in the study. Forty -four subjects, of whom at least 30% are male and at least 30% are female, were enrolled. These subjects were screened and then randomly assigned to three treatment groups.15 subjects received VXS-122330 mcg and 15 received VXS-122390 mcg. Fourteen subjects received VXS-1223U, for a total of 44 subjects. Subjects were randomized to receive treatment on Day 0 as follows: Treatment Arm 1: One VXS-122330 mcg and two inactive uncoated vaccine-free HD- MAPs (VXS-1223U) (total delivered estimate 15 mcg HexaPro) Treatment Arm 2: Three (3) VXS-122330 mcg (total delivered estimate 45 mcg HexaPro) Treatment Arm 3: Three inactive uncoated vaccine-free HD-MAPs (VXS-1223U) The study commenced with sentinel dosing where two subjects in Treatment Arm 1 (VXS-122330 mcg), and one subject in Treatment Arm 3 (VXS-1223U) were monitored for a minimum of 7 days. Safety data from the 3 sentinel subjects was reviewed by the Data Safety Review Committee. The goal was to evaluate the safety and tolerability of VXS-1223 (either 30 mcg or 90 mcg where estimated delivered dose is 15 mcg and 45 mcg respectively), compared with VXS-1223 and to evaluate the immune response of VXS-1223 (either 30 mcg or 90 mcg where estimated delivered dose is 15 mcg and 45 mcg respectively), compared with VXS-1223U VXS-1223 is an integrated, single-use, intradermal (ID) vaccine-delivery system, containing a mechanical, dome-spring that applies the array of micro-projections to the skin at approximately 20 m / s. The spring was actuated by pressing down on the top of the applicator with afinger and the whole delivery system (including the HD-MAP) was removed after 2 minutes (± 10 seconds) of application time. VXS-1223 (active) includes an aseptically produced 0.64 cm² polymer array (or ‘patch’) with approximately 1,700 microprojections, coated with 30 mcg of a modified SARS-CoV-2 spike protein (HexaPro), supplied by ExcellGene (Monthey, Switzerland). Based on an estimated 50% transfer of HexaPro into study participants, ~15 mcg of HexaPro will be delivered ID per VXS-1223 HD-MAP application. VXS-1223U (inactive) includes a terminally sterilised 0.64 cm² polymer patch, with approximately 1,700 micro- projections. The inactive HD-MAP does not include any coating of materials on the micro-projections, but all the other components on the ID-delivery system remain unchanged compared with VXS-1223. VXS-1223 (vaccine coated HD-MAP) and VXS-1223U (uncoated vaccine free HD-MAPs) were packaged in sealed foil pouches. VXS-1223 is stored at 2 to 8°C (do not freeze) and left in the complete packaging provided before use. Before use, the product was warmed to ambient temperature before opening the foil pouch. VXS-1223U are also packaged as described above. These were stored below 30°C (do not freeze) and were left at ambient temperature before use. On Day 0, prior to receiving the study assessment or treatment, subjects were tested for SARS-CoV-2 using a suitable Rapid Antigen Test (TGA approved). Only subjects with a negative RAT test will be included in the study and receive the study treatment. For all the subjects on Day 0, venous blood samples was collected for haematology and biochemistry, vital signs will be measured (blood pressure, heart rate, tympanic temperature and respiratory rate), and females will undergo a urine pregnancy test. On days 7, 28.56 and 90 subjects returned to the clinic for review of any local site reactions (tolerability and skin irritability), vital signs measurement, and for further application site photographs to be taken. All participants were tested for SARS-CoV-2 Rapid Antigen Test (RAT) testing before entering the site. Subjects will be asked about AEs or changes in concomitant medications. All subjects had blood and saliva samples taken for immunogenicity, and clinical laboratory analysis. SARS-COV-2 neutralising antibody in serum was assessed using a microneutralisation (MN) assay against Wuhan (wild-type) SARS-CoV-2, and delta (B.1.1.617.2) and omicron (B.1.1.529) variants of concern (VoC). Serum IgG binding to spike protein, receptor binding domain (RBD) and nucleocapsid (N) protein were assayed using a multiplex binding assay (Meso Scale Discovery, MSD). Binding to spike protein of several VoCs, including delta and omicron was assayed. Mucosal antibody IgA in saliva swabs binding to spike, RBD and N were assayed using a multiplex binding assay (MSD). Binding to spike protein of several VoCs, including delta and omicron were assayed. In addition, cell mediate immunity was evaluated for T cell CD4+ response using an intracellular cytokine stainingflow cytometry approach. Figure 1 shows the fold change on a per subject basis for each functional IgG assay by group. These results are antibodies against Wuhan strain RBD and spike (the vaccine strain). Thefigure demonstrates a clear positive response to HD-MAP treatment and this appears to be increased in the higher dose group. The following mean fold changes (as shown by the x on the box and whisker plots in thefigure) were determined for the treatment groups: Table 1 – Anti-RBD and Anti-Spike Mean Fold Change Group Anti-RBD mean fold change Day Anti-Spike mean fold change 28 Day 28 15µg dose (1 x active HD-MAP) 2.8 3.2 15µg dose (1 x active HD-MAP) 8.8 7.8 There is limited published data available from studies where mRNA vaccines have been used to give a 4thdose booster. In general, however, these have shown a similar level of boosting (approximately 6-fold) of anti-RBD (Wuhan strain) titres. The effect of subject day 0 titre on fold change at day 28 is shown in Figure 2 for the treatment groups in the anti-RBD assay. There is an apparent correlation between a high titre at day 0 and low fold increase and the opposite for a low incoming day 0 titre. This is like the results seen from the measles and rubella study with a variable incoming subject pool. The graph also highlights that distribution of titre range across the groups was not consistent, with the lower dose, 15 ug group, having a higher number of subjects with an elevated day 0 titre. The variability of the data can be seen in two linear plots for anti-RBD and anti-spike data as seen in Figure 3A and Figure 3B respectively. In this representation the “dose response” is less clear as it represents the mean titre per group not the individual participant response. Figure 4 is plotted on a log10 scale as shown below for the anti- RBD results with a similar outcome. Table2 – Anti-RBD and Anti-Spike Group Anti-RBD Anti-Spike #ULoQ D0 #ULoQ D28 #ULoQ D0 #ULoQ D28 Control 2 2 0 1 15µg HexaPro 2 3 0 1 45µg HexaPro 0 2 0 0 Example 2 Wear Time and Microprojection Morphology An integrated, single-use, intradermal (ID) vaccine-delivery system, containing a mechanical, dome-spring that applies the array of micro-projections to the skin at approximately 20 m / s was used in the study. The spring was actuated by pressing down on the top of the applicator with afinger and the whole delivery system (including the HD-MAP) was removed after 3 or 30 or 120 seconds. The MAP contained 2500 microprojections. One MAP configuration was a tip configuration which was a tapered microprojection with no discontinuations on a square base. The other configuration was a stepped configuration where there was a discontinuity in the microprojection. Both MAP configurations were coated with 30ug dose of HexaPro. The MAPs were delivered to the skin of pigs and left in the skin for 3, 30 and 120 seconds. Table 3 – Study Design Group 1 2 3 4 5 6 MAP configuration 2.5k square HexaPro dose per MAP (µg) 30 Coating Morphology Tip Step MAPs for Pig Application 4 6 4 4 6 4 Application time (s) 120 30 3 120 30 3 Table 4 – Membrane Transfer of HexaPro Group n Mean Transfer ST Dev %CV %CV (Elution Membrane (Transfer control) Membrane G1-3 3 79.1% 2.6% 3.3% 3.9% G4-6 2 85.3% 1.8% 2.1% 5.7% G7 3 87.4% 1.1% 1.3% 1.2% Table 5 - Membrane Transfer of HexaPro Group Coating Wear Time %DE n St Dev %CV (s) G1 tip 120 67.6% 4 3.2% 4.8% G2 Tip 120 81,4% 8 1.1% 1.4% The main factor in delivering the vaccine to the patient is stripping of the vaccine from the microprojections as opposed to the vaccine dissolving into the skin. There was over 60% delivery efficiency achieved after 3 second wear time. No statistical difference on wear time or morphology. (See Figures 11- 14). Example 3 Comparison of HD-MAP versus IM injection in mice Two doses of 1) HexaPro; 2) HexaPro alpha; 3) HexaPro delta; 4) HexaPro alpha + delta and excipient only were administered to mice on day 0 and day 21 either by administration with HD-MAP or by IM injection (Table 5). All vaccines administered included the excipient QS-21. Bleeds were taken on day 20 and day 42. Spleens were collected on day 42 for ICS analysis of T cell responses. Table 6 – HexaPro Admininstrations Group Vaccine Route Dose (µg) Adjuvant N 1 HexaPro HD-MAP 2 QS-21 6 2 HexaPro Alpha HD-MAP 2 QS-21 6 3 HexaPro Delta HD-MAP 2 QS-21 6 4 HexaPro Alpha + Delta HD-MAP 2 of each QS-21 6 5 Excipients Only HD-MAP 2 QS-21 6 6 HexaPro IM 2 QS-21 6 7 HexaPro Alpha IM 2 QS-21 6 8 HexaPro Delta IM 2 QS-21 6 9 HexaPro Alpha + Delta IM 2 of each QS-21 6 10 Excipients Only IM 2 QS-21 6 The results of the study are described in Figures 15-20. Example 4 Delta Challenge Study The study included 3 groups of n = 8 mice / group: 1) naïve, 2) 2µg HexaPro (Wuhan) HD-MAP + QS21 (3 µg) and 3) 2µg HexaPro (Wuhan) ID + QS21 (3 µg). Each group of mice was challenged with Delta SARS-CoV-2 21 days post-vaccination. Four mice from each group were culled for viral load assessment in the lungs. The results of the study are described in Figures 21-23. Example 5 HexaPro Delta Omicron Study The study included 5 groups of n = 8 mice / group: 1) naïve, 2) 2µg HexaPro Delta + Omicron HD-MAP 3) 2µg HexaPro Delta + Omicron + QS-21 HD-MAP, 4) 2µg HexaPro Delta + Omicron ID 3) 2µg HexaPro Delta + Omicron + QS21 ID Table 6 – HexaPro Admininstrations Group Vaccine dose 1 Vaccine dose 2 Route N 1 - - - 8 2 HexaPro HexaPro Delta + Omicron ID 8 3 Hexapro HexaPro Delta + Omicron HD-MAP 8 4 HexaPro + QS21 HexaPro Delta + Omicron ID 8 + QS21 5 HexaPro + QS21 HexaPro Delta + Omicron HD-MAP 8 + QS-21 The results of the study are described in Figures 24 and 25. Example 6 Spatial Transcriptomics Study Four groups of mice numbering from 3 -4 subjects were subjected to skin sampling at 1.4 and 24 hours post treatment and the skin samples were stained and read for transcriptomic analysis using a nanoString GEoMX analyzer (Seefigure 26A-D). The four groups were untreated normal skin, HD-MAP alone, HD- MAP coated with HexaPro and HD-MAP treated with HexaPro and QS21. The study indicated in the dermis inflammatory pathways were upregulated (TNF, 17, NOD-like signalling). In the epidermis genes associated with metabolism were upregulated due to wound healing and cell proliferation in response to the MAP application. See Figures 27-32.

Claims

Claims 1. A method of immunizing a human against SARS-CoV-2 by administering to the human a HexaPro vaccine composition coated onto a microprojection array (HD-MAP) comprising a base and a plurality of solid microprojections by projecting the microprojection array into the human’s skin thereby penetrating the skin with the microprojections coated with the composition such that the vaccine composition is stripped from the microprojections.

2. The method of claim 1 wherein the HexaPro vaccine composition is selected from the group consisting of HexaPro wild-type, HexaPro alpha, HexaPro beta, HexaPro gamma, HexaPro delta, HexaPro omicron and combinations thereof.

3. The method of claim 2 wherein the number of microprojections is between 1500 and 3000.

4. The method of claim 3 wherein the length of the microprojections is between 200 to 400µm.

5. The method of clam 2 wherein the HexaPro vaccine composition comprises a saponin.

6. The method of claim 5 wherein the saponin is QS-21.

7. The method of claim 1 wherein the HexaPro vaccine composition is a dose of between 15 to 30µg.

8. The method of claim 1 wherein the HexaPro vaccine composition is stable for 6 months at 2-8°C.

9. The method of claim 1 wherein the amount of HexaPro vaccine composition that is stripped from the microprojections is from about 50 to 90% of the amount of HexaPro vaccine composition coated onto the microprojections.

10. The method of claim 1 wherein the microprojection array is projected at the skin at a velocity of about 20 to 26 meters per second.

11. The method of claim 1 wherein the administration to the human is accomplished by multiple doses of the HexaPro vaccine composition.

12. The method of claim 1 wherein the microprojection array remains in the skin of the human for at least 3 seconds.